<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Nat Med</journal-id><journal-id journal-id-type="iso-abbrev">Nat Med</journal-id><journal-title-group><journal-title>Nature Medicine</journal-title></journal-title-group><issn pub-type="ppub">1078-8956</issn><issn pub-type="epub">1546-170X</issn><publisher><publisher-name>Nature Publishing Group US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40016450</article-id><article-id pub-id-type="pmc">PMC12092302</article-id>
<article-id pub-id-type="publisher-id">3512</article-id><article-id pub-id-type="doi">10.1038/s41591-025-03512-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8894-3545</contrib-id><name><surname>Long</surname><given-names>Georgina V.</given-names></name><address><email>georgina.long@sydney.edu.au</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6155-1020</contrib-id><name><surname>Shklovskaya</surname><given-names>Elena</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7435-0834</contrib-id><name><surname>Satgunaseelan</surname><given-names>Laveniya</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1863-512X</contrib-id><name><surname>Mao</surname><given-names>Yizhe</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>da Silva</surname><given-names>In&#x000ea;s Pires</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Perry</surname><given-names>Kristen A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8433-4336</contrib-id><name><surname>Diefenbach</surname><given-names>Russell J.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Gide</surname><given-names>Tuba N.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Shivalingam</surname><given-names>Brindha</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Buckland</surname><given-names>Michael E.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2197-6657</contrib-id><name><surname>Gonzalez</surname><given-names>Maria</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Caixeiro</surname><given-names>Nicole</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Vergara</surname><given-names>Ismael A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Bai</surname><given-names>Xinyu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Rawson</surname><given-names>Robert V.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Hsiao</surname><given-names>Edward</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Palendira</surname><given-names>Umaimainthan</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4909-2984</contrib-id><name><surname>Phan</surname><given-names>Tri Giang</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Menzies</surname><given-names>Alexander M.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Carlino</surname><given-names>Matteo S.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff11">11</xref><xref ref-type="aff" rid="Aff12">12</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1244-961X</contrib-id><name><surname>Quek</surname><given-names>Camelia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8102-7998</contrib-id><name><surname>Grimmond</surname><given-names>Sean M.</given-names></name><xref ref-type="aff" rid="Aff13">13</xref><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0435-6824</contrib-id><name><surname>Vissers</surname><given-names>Joseph H. A.</given-names></name><xref ref-type="aff" rid="Aff13">13</xref><xref ref-type="aff" rid="Aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Yeo</surname><given-names>Dannel</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3181-7198</contrib-id><name><surname>Rasko</surname><given-names>John E. J.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff15">15</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3249-9849</contrib-id><name><surname>Khasraw</surname><given-names>Mustafa</given-names></name><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name><surname>Neyns</surname><given-names>Bart</given-names></name><xref ref-type="aff" rid="Aff17">17</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6674-0157</contrib-id><name><surname>Reardon</surname><given-names>David A.</given-names></name><xref ref-type="aff" rid="Aff18">18</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4754-5900</contrib-id><name><surname>Ashley</surname><given-names>David M.</given-names></name><xref ref-type="aff" rid="Aff16">16</xref></contrib><contrib contrib-type="author"><name><surname>Wheeler</surname><given-names>Helen</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Back</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff19">19</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8991-0013</contrib-id><name><surname>Scolyer</surname><given-names>Richard A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff7">7</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Drummond</surname><given-names>James</given-names></name><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff20">20</xref><xref ref-type="aff" rid="Aff21">21</xref></contrib><contrib contrib-type="author"><name><surname>Wilmott</surname><given-names>James S.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2094-9198</contrib-id><name><surname>Rizos</surname><given-names>Helen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0384j8v12</institution-id><institution-id institution-id-type="GRID">grid.1013.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 834X</institution-id><institution>Melanoma Institute Australia, University of Sydney, </institution></institution-wrap>Sydney, New South Wales Australia </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0384j8v12</institution-id><institution-id institution-id-type="GRID">grid.1013.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 834X</institution-id><institution>Faculty of Medicine and Health, University of Sydney, </institution></institution-wrap>Sydney, New South Wales Australia </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0384j8v12</institution-id><institution-id institution-id-type="GRID">grid.1013.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 834X</institution-id><institution>Charles Perkins Centre, University of Sydney, </institution></institution-wrap>Camperdown, New South Wales Australia </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.513227.0</institution-id><institution>Mater Hospital, </institution></institution-wrap>North Sydney, New South Wales Australia </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02gs2e959</institution-id><institution-id institution-id-type="GRID">grid.412703.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0587 9093</institution-id><institution>Royal North Shore Hospital, </institution></institution-wrap>St Leonards, New South Wales Australia </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01sf06y89</institution-id><institution-id institution-id-type="GRID">grid.1004.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2158 5405</institution-id><institution>Macquarie University, </institution></institution-wrap>Macquarie Park, New South Wales Australia </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05gpvde20</institution-id><institution-id institution-id-type="GRID">grid.413249.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0385 0051</institution-id><institution>Royal Prince Alfred Hospital, </institution></institution-wrap>Camperdown, New South Wales Australia </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00qeks103</institution-id><institution-id institution-id-type="GRID">grid.419783.0</institution-id><institution>Chris O&#x02019;Brien Lifehouse, </institution></institution-wrap>Camperdown, New South Wales Australia </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03tb4gf50</institution-id><institution-id institution-id-type="GRID">grid.416088.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 0753 1056</institution-id><institution>NSW Health Pathology, </institution></institution-wrap>Sydney, New South Wales Australia </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01b3dvp57</institution-id><institution-id institution-id-type="GRID">grid.415306.5</institution-id><institution-id institution-id-type="ISNI">0000 0000 9983 6924</institution-id><institution>Garvan Institute of Medical Research, </institution></institution-wrap>Darlinghurst, New South Wales Australia </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/017bddy38</institution-id><institution-id institution-id-type="GRID">grid.460687.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0572 7882</institution-id><institution>Blacktown Hospital, </institution></institution-wrap>Blacktown, New South Wales Australia </aff><aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04gp5yv64</institution-id><institution-id institution-id-type="GRID">grid.413252.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 0180 6477</institution-id><institution>Westmead Hospital, </institution></institution-wrap>Westmead, New South Wales Australia </aff><aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01ej9dk98</institution-id><institution-id institution-id-type="GRID">grid.1008.9</institution-id><institution-id institution-id-type="ISNI">0000 0001 2179 088X</institution-id><institution>Collaborative Centre for Genomic Cancer Medicine, </institution><institution>University of Melbourne, </institution></institution-wrap>Melbourne, Victoria Australia </aff><aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01ej9dk98</institution-id><institution-id institution-id-type="GRID">grid.1008.9</institution-id><institution-id institution-id-type="ISNI">0000 0001 2179 088X</institution-id><institution>Department of Clinical Pathology, </institution><institution>University of Melbourne, </institution></institution-wrap>Melbourne, Victoria Australia </aff><aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05gvja138</institution-id><institution-id institution-id-type="GRID">grid.248902.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0444 7512</institution-id><institution>Centenary Institute, </institution></institution-wrap>Camperdown, New South Wales Australia </aff><aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00py81415</institution-id><institution-id institution-id-type="GRID">grid.26009.3d</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7961</institution-id><institution>Duke University, </institution></institution-wrap>Durham, NC USA </aff><aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/038f7y939</institution-id><institution-id institution-id-type="GRID">grid.411326.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0626 3362</institution-id><institution>Universitair Ziekenhuis Brussel, </institution></institution-wrap>Brussels, Belgium </aff><aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02jzgtq86</institution-id><institution-id institution-id-type="GRID">grid.65499.37</institution-id><institution-id institution-id-type="ISNI">0000 0001 2106 9910</institution-id><institution>Center for Neuro-Oncology, </institution><institution>Dana-Farber Cancer Institute, </institution></institution-wrap>Boston, MA USA </aff><aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0384j8v12</institution-id><institution-id institution-id-type="GRID">grid.1013.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 834X</institution-id><institution>Sydney Medical School, University of Sydney, </institution></institution-wrap>Sydney, New South Wales Australia </aff><aff id="Aff20"><label>20</label>North Shore Radiology &#x00026; Nuclear Medicine, St Leonards, New South Wales Australia </aff><aff id="Aff21"><label>21</label>Brain Imaging Laboratory, The Brain Cancer Group, St Leonards, New South Wales Australia </aff></contrib-group><pub-date pub-type="epub"><day>27</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>27</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>31</volume><issue>5</issue><fpage>1557</fpage><lpage>1566</lpage><history><date date-type="received"><day>24</day><month>7</month><year>2024</year></date><date date-type="accepted"><day>14</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025, corrected publication 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par3">Glioblastoma (GBM) is an aggressive primary adult brain tumor that rapidly recurs after standard-of-care treatments, including surgery, chemotherapy and radiotherapy. While immune checkpoint inhibitor therapies have transformed outcomes in many tumor types, particularly when used neoadjuvantly or as a first-line treatment, including in melanoma brain metastases, they have shown limited efficacy in patients with resected or recurrent GBM. The lack of efficacy has been attributed to the scarcity of tumor-infiltrating lymphocytes (TILs), an immunosuppressive tumor microenvironment and low tumor mutation burden typical of GBM tumors, plus exclusion of large molecules from the brain parenchyma. We hypothesized that upfront neoadjuvant combination immunotherapy, administered with disease in situ, could induce a stronger immune response than treatment given after resection or after recurrence. Here, we present a case of newly diagnosed IDH<italic>-</italic>wild-type, <italic>MGMT</italic> promoter unmethylated GBM, treated with a single dose of neoadjuvant triplet immunotherapy (anti-programmed cell death protein 1 plus anti-cytotoxic T-lymphocyte protein 4 plus anti-lymphocyte-activation gene 3) followed by maximal safe resection 12 days later. The anti-programmed cell death protein 1 drug was bound to TILs in the resected GBM and there was marked TIL infiltration and activation compared with the baseline biopsy. After 17 months, there is no definitive sign of recurrence. If used first line, before safe maximal resection, checkpoint inhibitors are capable of immune activation in GBM and may induce a response. A clinical trial of first-line neoadjuvant combination checkpoint inhibitor therapy in newly diagnosed GBM is planned (GIANT; trial registration no. <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT06816927">NCT06816927</ext-link>).</p></abstract><abstract id="Abs2" abstract-type="web-summary"><p id="Par4">A patient with newly diagnosed glioblastoma was safely treated with neoadjuvant nivolumab, relatlimab and ipilimumab before maximal resection, with comprehensive immune profiling showing the induction of overall immune activation early during treatment. The patient had no definitive evidence of recurrence at 17 months after treatment.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>CNS cancer</kwd><kwd>Tumour immunology</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100000925</institution-id><institution>Department of Health | National Health and Medical Research Council (NHMRC)</institution></institution-wrap></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001171</institution-id><institution>Cancer Institute NSW (Cancer Institute New South Wales)</institution></institution-wrap></funding-source><award-id>2020/ECF1244</award-id><award-id>2020/ECF1153</award-id><award-id>2021/CBG0002</award-id><principal-award-recipient><name><surname>Gide</surname><given-names>Tuba N.</given-names></name><name><surname>Quek</surname><given-names>Camelia</given-names></name><name><surname>Yeo</surname><given-names>Dannel</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100001774</institution-id><institution>University of Sydney</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Nature America, Inc. 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Main</title><p id="Par5">Glioblastoma (GBM) is the most aggressive form of adult-type diffuse glioma and is characterized by the absence of <italic>IDH1</italic> and <italic>IDH2</italic> mutations<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Standard therapy, of maximal safe resection followed by radiotherapy and temozolomide chemotherapy (the Stupp protocol<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>), provides a 2.5-month median overall survival (OS) benefit over surgery with radiotherapy alone in unselected IDH-agnostic patients with GBM<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. Patients with <italic>MGMT</italic> promoter-unmethylated GBM have the worst outcomes, with a median OS of 14.1 months despite standard-of-care chemoradiotherapy<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. Most patients will die within the first 2 years of diagnosis<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>.</p><p id="Par6">Immune checkpoint inhibitors (ICIs) have revolutionized the management of many cancer types, including melanoma, where the 10-year melanoma-specific survival rate has increased from less than 5% to 52% of patients in stage IV treated with combination ICIs<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. In randomized GBM trials, adjuvant anti-programmed cell death protein 1 (PD-1) administered in combination with radiotherapy (plus temozolomide in methylated GBM) after maximal safe resection and followed by anti-PD-1 monotherapy to 12 months, showed no benefit over the standard Stupp protocol<sup><xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref></sup>. The lack of ICI activity in GBM is thought to reflect a low tumor mutational burden (TMB) and an immunosuppressive tumor microenvironment (TME) characterized by abundant microglia and macrophages, a scarcity of tumor-infiltrating lymphocytes (TILs) and immature natural killer cells<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR9">9</xref></sup>.</p><p id="Par7">Neoadjuvant ICI outperforms adjuvant delivery in many cancer types but has only been tested using single-agent anti-PD-1 in small numbers of heavily pretreated (corticosteroids and chemoradiotherapy) patients with recurrent GBM<sup><xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref></sup> (Extended Data Table <xref rid="Tab1" ref-type="table">1</xref>). In these patients, neoadjuvant PD-1 blockade promoted the activation of TILs<sup><xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref></sup> and extended OS (13.7 months with neoadjuvant ICI versus 7.5 months with adjuvant)<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. Notably, two of three newly diagnosed patients with GBM who received neoadjuvant anti-PD-1 before maximal safe resection remained disease free for more than 33 and 28 months, respectively<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. Response to neoadjuvant immunotherapy may be supported by the presence of tumor-associated effector CD8<sup>+</sup> T cells identified in the cranial bone marrow of treatment-naive, newly diagnosed patients with GBM<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>.</p><p id="Par8">Here, we describe a case study of a newly diagnosed patient with GBM (IDH-wild-type, unmethylated <italic>MGMT</italic> promoter) treated with triplet neoadjuvant ICI upfront (nivolumab, anti-PD-1; ipilimumab, anti-cytotoxic T-lymphocyte protein 4 (CTLA-4); and relatlimab, anti-lymphocyte-activation gene 3 (LAG3)), before maximal safe resection. Triple ICI therapy was selected based on an unprecedented survival in the phase 1 trial in advanced melanoma<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>, as well as the significantly superior activity of the combination of multiple ICIs versus ICI monotherapy in melanoma with a poor TME<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR17">17</xref></sup> (low CD8<sup>+</sup> T cells, low TMB and low interferon-&#x003b3; (IFN&#x003b3;)), metastases to the brain<sup><xref ref-type="bibr" rid="CR18">18</xref></sup> or primary resistance to anti-PD-1 therapy<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>&#x02014;all features found in GBM. Our findings confirm the urgent need to investigate this strategy in clinical trials.</p></sec><sec id="Sec2"><title>Patient and GBM characteristics</title><p id="Par9">A previously well 56-year-old male presented with new-onset generalized seizure and no prior symptoms (pre-ICI treatment, day &#x02212;14). After initial management (Supplementary Results <xref rid="MOESM1" ref-type="media">1</xref>), the patient was diagnosed with a left temporal lobe GBM (IDH-wild-type, central nervous system WHO grade 4, RTK2 subtype (DKFZ calibrated score&#x02009;=&#x02009;0.94)) after an open craniotomy biopsy (pre-ICI treatment, day &#x02212;4; Fig. <xref rid="Fig1" ref-type="fig">1a</xref>). The tumor was a pleomorphic, mitotically active, diffusely infiltrative astrocytic glioma with negative IDH1 (R132H) immunohistochemistry (IHC) and retained nuclear ATRX stain. Mitoses were present at up to 8&#x02013;10 per ten high-power fields (field diameter&#x02009;=&#x02009;0.58&#x02009;mm). There was no evidence of microvascular proliferation or necrosis (Supplementary Results <xref rid="MOESM1" ref-type="media">2</xref>). Pyrosequencing revealed a <italic>TERT</italic> promoter mutation (C228T) and confirmed no <italic>IDH1</italic> codon 132 or <italic>IDH2</italic> codon 172 mutation. The tumor was unmethylated at the <italic>MGMT</italic> promoter region. Moderate-to-strong p53 nuclear staining was observed in tumor cells. Microsatellite status was stable. Whole-genome sequencing (WGS) (mean coverage&#x02009;=&#x02009;85X) revealed focal amplification of the <italic>EGFR</italic> and <italic>MDM4</italic> genes, homozygous <italic>PTEN</italic> deletion and inactivating rearrangement of <italic>RB1</italic> with a low TMB (two mutations per megabase; Fig. <xref rid="Fig1" ref-type="fig">1b</xref> and Extended Data Table <xref rid="Tab2" ref-type="table">2</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><title>Clinical and molecular details of the patient with GBM and treatment regimen.</title><p><bold>a</bold>, Serial magnetic resonance imaging scans with gadolinium including T2-weighted (top) and fluid-attenuated inversion recovery sequences (bottom) shown during the treatment schedule. The treatment time points, relative to neoadjuvant ICI therapy initiation (day +1) are shown, including ICI cycles (blue), radiotherapy (green) and peptide vaccine doses (yellow). The peptide vaccine program was recently completed, and ongoing analyses will be reported separately. The most recent scan (day +526) demonstrated grossly stable postsurgical changes with persistent white matter T2 fluid-attenuated inversion recovery hyperintensity in the left temporal periventricular white matter posterior to the temporal pole surgical bed and the left temporal operculum. There was a stable small focus of enhancement lateral to the left temporal horn. These changes were all within the high-dose radiotherapy field. No focal hyperperfusion or diffusion restriction to suggest recurrent disease was observed. <bold>b</bold>, Key genomic events identified in pretreatment GBM. Segment-level copy number profile across chromosomes includes amplifications in red (copy number&#x02009;&#x0003e;&#x02009;2.5) and deletions in blue (copy number&#x02009;&#x0003c;&#x02009;1.5). Copy number-neutral regions are shown in black. For copy number, the <italic>y</italic> axis is shown in pseudo-logarithmic scale. Somatic mutations (magenta) and rearrangements (dark green) of potential clinical significance or in known cancer genes are included in the genomic region where each gene resides together with their allele fraction (AF). All events were identified based on the WGS of the pretreatment (day &#x02013;4) tumor specimen, except for the <italic>EGFR</italic> (R108K) mutation identified based on the WGS of the resection (posttreatment; day +13) specimen.</p></caption><graphic xlink:href="41591_2025_3512_Fig1_HTML" id="d33e804"/></fig></p><p id="Par10">The patient&#x02019;s Eastern Cooperative Oncology Group Performance Status fluctuated between 0 and 1 because of postictal symptoms, surgery and lumbar punctures in the initial 4 weeks after presentation. In the 2 weeks before the initiation of treatment, there was no evidence of tumor growth or peritumoral edema on imaging. Corticosteroids were not commenced at any time point.</p></sec><sec id="Sec3"><title>Neoadjuvant combined (triplet) ICI and outcomes</title><p id="Par11">After treatment with intravenous neoadjuvant triplet ICI on day +1 (cycle 1: nivolumab 480&#x02009;mg plus relatlimab 160&#x02009;mg plus ipilimumab 80&#x02009;mg), the patient underwent safe maximal resection (day +13; Supplementary Results <xref rid="MOESM1" ref-type="media">3</xref>), a 6-week course of adjuvant radiotherapy from day +35 (60&#x02009;Gy in 30 fractions), adjuvant ICI from day +47 and adjuvant personalized peptide vaccination from day +91 (Fig. <xref rid="Fig1" ref-type="fig">1</xref> and Extended Data Table <xref rid="Tab3" ref-type="table">3</xref>). Adjuvant ICIs were administered as monotherapy or in combination, depending on toxicity and with avoidance of corticosteroids (grade 1 (and after cycle 12, grade 3) hepatitis, grade 1 conjunctivitis and grade 1 dermatitis attributed to ipilimumab). Circulating tumor cells (CTCs) (4&#x02032;,6-diamidino-2-phenylindole (DAPI)&#x02009;+&#x02009;glial fibrillary acidic protein (GFAP)&#x02009;+&#x02009;epidermal growth factor receptor (EGFR)&#x02009;+&#x02009;CD45<sup>&#x02212;</sup>CD66b<sup>&#x02212;</sup>) zero-converted after therapy (16 CTCs in 7.5&#x02009;ml blood detected on day &#x02212;9 versus zero CTCs on day +190; Extended Data Fig. <xref rid="Fig6" ref-type="fig">1</xref>). At the last radiographic assessment (day +526, 17 months), there was no definitive evidence of recurrence (Fig. <xref rid="Fig1" ref-type="fig">1a</xref>).</p></sec><sec id="Sec4"><title>Neoadjuvant ICI reshapes the GBM immune landscape</title><p id="Par12">Chromogenic IHC and high-plex immunofluorescence of pretreatment (day &#x02212;4) and posttreatment (day +13) formalin-fixed paraffin-embedded tumor specimens confirmed increases in the number of CD3<sup>+</sup> T cells (Fig. <xref rid="Fig2" ref-type="fig">2a,b</xref>), including CD3<sup>+</sup>CD4<sup>+</sup> T cells (greater than tenfold increase in the posttreatment specimen relative to pretreatment (from 0.3% to 5%)) and CD3<sup>+</sup>CD8<sup>+</sup> cytotoxic T cells (eightfold increase posttreatment relative to pretreatment (from 0.4% to 3%); Fig. <xref rid="Fig2" ref-type="fig">2b</xref>). To account for potential localized inflammation induced by the initial biopsy, we confirmed a global increase in infiltration of CD3<sup>+</sup> T cells via chromogenic IHC across all posttreatment tumor sections analyzed from the left temporal and amygdala regions (up to 30&#x02009;mm from the biopsy site), compared with the pretreatment biopsy tissue (Extended Data Fig. <xref rid="Fig7" ref-type="fig">2</xref>). This contrasted with our findings in a resection sample from a separate patient with an untreated right frontal GBM, showing only a very localized T cell infiltrate due to the diagnostic biopsy performed 14 days before the resection (nearly zero T cells 8&#x02009;mm from the biopsy site; Extended Data Fig. <xref rid="Fig7" ref-type="fig">2</xref>). High-dimensional-spatial phenotyping of formalin-fixed paraffin-embedded GBM specimens revealed increased colocalization of CD4<sup>+</sup> and CD8<sup>+</sup> T cells with tumor cells, and a notable decrease in the colocalization of macrophages and microglial cells with tumor cells in response to neoadjuvant ICI treatment (Fig. <xref rid="Fig2" ref-type="fig">2b</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><title>Evaluation of immune cells in the GBM tumor before (day &#x02212;4) and after (day +13) neoadjuvant ICI treatment.</title><p><bold>a</bold>, Representative region of whole-slide hematoxylin and eosin (H&#x00026;E) and IHC images of paired pretreatment and posttreatment GBM specimens for CD3<sup>+</sup>, CD8<sup>+</sup> and CD4<sup>+</sup> T cells. Representative images were taken from areas of increased tumor cellularity. <bold>b</bold>, Representative region of whole-slide high-plex immunofluorescence images and cellular neighborhood enrichment analysis showing the co-occurrence of specific immune cells (CD8<sup>+</sup> T and CD4<sup>+</sup> T cells, dendritic cells (DCs), macrophages and glia) with tumor cells in the paired pretreatment and posttreatment GBM specimens. One slide was prepared and representative images were taken from areas of increased tumor cellularity. <bold>c</bold>, The tumor-infiltrating CD45<sup>+</sup> (immune) fraction was analyzed for T cell content (CD3<sup>+</sup>), T cell subsets (CD8<sup>+</sup>, CD4<sup>+</sup>FOXP3<sup>&#x02212;</sup> T<sub>EM</sub> and CD4<sup>+</sup>FOXP3<sup>+</sup> T<sub>reg</sub> cells) and activation markers (PD-1<sup>+</sup>Ki-67<sup>+</sup>). PD-1 expression on T cells was detected with anti-PD-1-Brilliant Violet 421 (BV421) in the pretreatment tumor or anti-IgG4-PE (detects nivolumab bound to PD-1) in the posttreatment tumor. <bold>d</bold>, The fraction of activated and proliferating T cell subsets, along with their GzmB expression, were evaluated in the posttreatment GBM. There was insufficient material available for analysis of the T cell subsets in the pretreatment biopsy specimen. <bold>e</bold>, Heatmap showing the immune activation transcriptome gene set<sup><xref ref-type="bibr" rid="CR36">36</xref></sup> scores (derived from the singscore method<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>) in the pretreatment and posttreatment tumor specimens (RNA was analyzed in triplet for each tumor specimen using the NanoString PanCancer IO360 Panel). <bold>f</bold>, The posttreatment tumor was analyzed for drug/nivolumab occupancy of PD-1 sites (nivolumab detection, staining with anti-IgG4-PE) and residual unoccupied PD-1 sites (PD-1 detection, staining with anti-PD-1 (CD279)-BV421). Scale bars = 100&#x02009;&#x000b5;m.</p><p><xref rid="MOESM3" ref-type="media">Source data</xref></p></caption><graphic xlink:href="41591_2025_3512_Fig2_HTML" id="d33e939"/></fig></p><p id="Par13">Multiparameter flow cytometry analysis was performed on the freshly dissociated pretreatment and posttreatment GBM specimens, and on an unrelated series of 11 primary GBM tumors resected from patients undergoing their first surgery. The CD45<sup>+</sup> immune cell content in the 12 pretreatment GBMs ranged from 0.4% to 34.0% of the total viable cell population (median&#x02009;=&#x02009;8.7%; Extended Data Fig. <xref rid="Fig8" ref-type="fig">3</xref>). The frequency of tumor-infiltrating CD3<sup>+</sup> (range&#x02009;=&#x02009;3&#x02013;23%; median&#x02009;=&#x02009;9.5%), CD4<sup>+</sup>FOXP3<sup>&#x02212;</sup> effector memory (T<sub>EM</sub>) (range&#x02009;=&#x02009;1&#x02013;12%; median&#x02009;=&#x02009;3.2%), CD4<sup>+</sup>FOXP3<sup>+</sup> regulatory T (T<sub>reg</sub>) cells (range&#x02009;=&#x02009;0&#x02013;2.5%; median&#x02009;=&#x02009;0.3%) and CD8<sup>+</sup> T cells (range&#x02009;=&#x02009;1&#x02013;9%; median&#x02009;=&#x02009;4.3%) were also variable in the pretreatment GBM specimens (Extended Data Fig. <xref rid="Fig8" ref-type="fig">3</xref>). After ICI treatment, the posttreatment GBM specimen showed a marked increase in the relative proportion of T cells, with CD3<sup>+</sup> T cells rising from 9.8% to 32.7%, CD4<sup>+</sup> T<sub>EM</sub> cells from 5.1% to 19.0%, CD4<sup>+</sup> T<sub>reg</sub> cells from 0.4% to 4.5% and CD8<sup>+</sup> T cells from 3.9% to 8.2% (Extended Data Fig. <xref rid="Fig8" ref-type="fig">3</xref>). When compared with 31 pretreatment primary GBM tumors (12 from this study and 19 from a published series<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>), the ICI-treated posttreatment GBM specimen had the highest proportion of infiltrating CD3<sup>+</sup> and CD4<sup>+</sup> T cells and among the highest frequency of infiltrating CD8<sup>+</sup> T cells.</p><p id="Par14">Further analyses of the paired pretreatment and posttreatment GBM revealed that the activated (PD-1<sup>+</sup>Ki-67<sup>+</sup>) tumor-infiltrating immune fraction increased 8.5-fold (from 5.2% to 44.2%) after neoadjuvant ICI therapy and was dominated by CD4<sup>+</sup> T<sub>EM</sub> cells (65.3%), followed by CD8<sup>+</sup> (21.5%) and T<sub>reg</sub> cells (12.4%; Fig. <xref rid="Fig2" ref-type="fig">2c,d</xref>). Activated granzyme B (GzmB)-expressing CD8<sup>+</sup>, CD4<sup>+</sup> T<sub>EM</sub> and CD4<sup>+</sup> T<sub>reg</sub> cells were also abundant (91%, 37% and 27%, respectively) in the posttreatment tumor (Fig. <xref rid="Fig2" ref-type="fig">2d</xref>). Transcriptome signatures indicative of immune cell activation, including IFN&#x003b3;, chemokine, costimulatory and tumor inflammation gene sets were all elevated in the GBM tumor after ICI treatment (Fig. <xref rid="Fig2" ref-type="fig">2e</xref>). These changes in immune cell activity corresponded with complete occupancy of PD-1 by nivolumab on tumor-infiltrating CD8<sup>+</sup> T, CD4<sup>+</sup> T<sub>EM</sub> and CD4<sup>+</sup> T<sub>reg</sub> cells in response to treatment (Fig. <xref rid="Fig2" ref-type="fig">2f</xref>). The expression of tumor major histocompatibility complex (MHC) classes I and II was examined after treatment; 83.8%, 75.3% and 72.7% of GFAP<sup>+</sup>/SOX2<sup>+</sup> GBM cells expressed MHC class I, MHC class II or both MHC classes I and II, respectively (Fig. <xref rid="Fig3" ref-type="fig">3a</xref>). The immune checkpoints&#x02014;LAG3, TIM3, CTLA-4, TIGIT and CD39&#x02014;were all highly expressed in tumor-infiltrating T cells after treatment (Fig. <xref rid="Fig3" ref-type="fig">3b</xref>). Although there was insufficient pretreatment biopsy material to confirm checkpoint induction in response to ICI therapy in infiltrating immune cells, checkpoint expression was potently induced from before to after neoadjuvant therapy in peripheral blood cell subsets (Fig. <xref rid="Fig4" ref-type="fig">4a,b</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><title>Flow cytometry tumor gating strategy and immune checkpoint analysis.</title><p><bold>a</bold>, General gating strategy for tumor dissociates. Left to right, a viability gate to exclude dead cells, a time gate to exclude electronic noise, a singlet gate to exclude doublets and tumor and immune fraction gates to define the cells of interest. Tumor cells (SOX2<sup>+</sup>) were further gated for the GFAP<sup>+</sup> fraction and analyzed for MHC class I (HLA-A, HLA-B, HLA-C) and MHC class II (HLA-DR, HLA-DP, HLA-DQ) expression. The numbers indicate the percentage of cells in the respective gates. T cell analysis is shown for comparison. <bold>b</bold>, The tumor-infiltrating CD45<sup>+</sup> (immune) fraction was analyzed for T cell content (CD3<sup>+</sup>), T cell subsets (CD8<sup>+</sup> T, CD4<sup>+</sup>FOXP3<sup>&#x02212;</sup> T<sub>EM</sub> and CD4<sup>+</sup>FOXP3<sup>+</sup> T<sub>reg</sub> cells), and immune checkpoints (CD39, LAG3, TIGIT, TIM3 and CTLA-4). The numbers indicate the percentage of cells in the respective gates. BUV, brilliant ultra-violet; FSC, forward scatter; FSC-A, forward scatter area; FSC-H, forward scatter height; SSC, side scatter; SSC-A, side scatter area.</p><p><xref rid="MOESM3" ref-type="media">Source data</xref></p></caption><graphic xlink:href="41591_2025_3512_Fig3_HTML" id="d33e1097"/></fig><fig id="Fig4"><label>Fig. 4</label><caption><title>Evaluation of circulating T cells before and after neoadjuvant ICI treatment.</title><p><bold>a</bold>, General gating strategy for PBMC samples. Left to right, a debris exclusion gate, a time gate to exclude electronic noise, a singlet gate to exclude doublets and a viability gate to exclude dead cells. T cells (CD3<sup>+</sup> SSC-A-low) were gated for CD45RA<sup>&#x02212;</sup>CD45RO<sup>+</sup> effector and memory subsets: CD8<sup>+</sup> T<sub>EM</sub> (CD3<sup>+</sup>CD8<sup>+</sup>CD45RA<sup>&#x02212;</sup>CD45RO<sup>+</sup>), CD4<sup>+</sup> T<sub>EM</sub> (CD3<sup>+</sup>CD4<sup>+</sup>FOXP3<sup>&#x02212;</sup>CD45RA<sup>&#x02212;</sup>CD45RO<sup>+</sup>) and T<sub>reg</sub> (CD3<sup>+</sup>CD4<sup>+</sup>FOXP3<sup>+</sup>CD45RA<sup>&#x02013;</sup>CD45RO<sup>+</sup>) cells. <bold>b</bold>, CD8<sup>+</sup> T<sub>EM</sub>, CD4<sup>+</sup> T<sub>EM</sub> and T<sub>reg</sub> subsets in the pretreatment (day &#x02212;4, left) and posttreatment (day +12, right) samples were analyzed for (top to bottom): T cell-bound nivolumab (detected with anti-IgG4-PE), residual unoccupied PD-1 (direct PD-1 detection with anti-PD-1 (CD279) BV421), activation markers (MHC class II, OX40) and GzmB. Immune checkpoint (LAG3, CTLA-4, TIGIT) expression analysis was performed on pretreatment (day &#x02212;9) samples. The numbers indicate the percentage of cells in the respective gates.</p><p><xref rid="MOESM3" ref-type="media">Source data</xref></p></caption><graphic xlink:href="41591_2025_3512_Fig4_HTML" id="d33e1172"/></fig></p><p id="Par15">The number of productive T cell receptor (TCR)&#x003b2; and TCR&#x003b3; clonotypes and the Shannon diversity index of TCR&#x003b2; and TCR&#x003b3; increased in the posttreatment tumor sample compared with the pretreatment specimen (Fig. <xref rid="Fig5" ref-type="fig">5a</xref>). Increased TCR diversity was associated with increased Shannon equitability (that is, similarity of clone frequency; Fig. <xref rid="Fig5" ref-type="fig">5a</xref>), confirming a more diverse TCR repertoire with reduced TCR clone dominance after neoadjuvant ICI therapy (Fig. <xref rid="Fig5" ref-type="fig">5b</xref>). TCR clone sharing analysis confirmed that 63.65% of TCR&#x003b2; clones were uniquely identified in the tumor after treatment, whereas 28.21% of TCR&#x003b2; clones infiltrating the tumor after ICI therapy were also detected in the circulation (Fig. <xref rid="Fig5" ref-type="fig">5c,d</xref>). Importantly, TCR&#x003b2; clones shared between the pretreatment, posttreatment and peripheral blood mononuclear cell (PBMC) samples were the most expanded clones (that is, TCR clones with more than 1% of the sample total TCR reads; Fig. <xref rid="Fig5" ref-type="fig">5e</xref>). These data suggest early clonal expansion of preexisting clonotypes.<fig id="Fig5"><label>Fig. 5</label><caption><title>Neoadjuvant ICI-induced TCR repertoire and immune cell changes.</title><p><bold>a</bold>, TCR&#x003b2; and TCR&#x003b3; clone numbers, Shannon diversity index and Shannon equitability index scores (measurement of the similarity of clone sizes) increased after neoadjuvant ICIs in the tumor (pretreatment (day &#x02212;4) and posttreatment (day +13)) and blood specimens (pretreatment (day &#x02212;9) and posttreatment (days +7 and +12)). <bold>b</bold>, The TCR clone size (clonotype total reads expressed as a percentage of total productive reads) of the 25 largest TCR clonotypes in each sample. The largest clones are at the bottom of each column. <bold>c</bold>, Upset plot of the shared TCR&#x003b2; clonotypes across tumor (before and after) and blood specimens (day &#x02212;9, day +7, day +12). The vertical bars indicate the number of clonotypes; the sample distribution patterns are indicated below the chart and are represented by filled points linked by the lines. A filled circle indicates that clones were detected in the corresponding samples; a gray circle indicates that TCR clones were not detected. The first five vertical bars show clonotypes unique to each of the specimens. The horizontal bars (lower left) show the number of TCR&#x003b2; clones in each sample. <bold>d</bold>, Tracking the origin of clonotypes detected in the posttreatment tumor specimen. TCR&#x003b2; clonotypes were classified based on whether they were unique to the posttreatment sample (63.65% of clonotypes) or shared with any of the PBMC samples (blood), the pretreatment tumor sample or both the pretreatment tumor and blood. The number in the center indicates the number of productive TCR&#x003b2; clonotypes in the posttreatment tumor sample. <bold>e</bold>, Details of the size (clonotype total reads/sample total reads expressed as a percentage) of TCR&#x003b2; clonotypes identified in the posttreatment tumor according to their origin (that is, identified in PBMC sample (blood), the pretreatment tumor sample or both the pretreatment tumor and blood samples). Most expanded clones (accounting for more than 1% of the sample total reads) were shared with the pretreatment tumor and blood samples.</p><p><xref rid="MOESM3" ref-type="media">Source data</xref></p></caption><graphic xlink:href="41591_2025_3512_Fig5_HTML" id="d33e1216"/></fig></p></sec><sec id="Sec5"><title>Dynamic changes in peripheral immune markers</title><p id="Par16">Analysis of circulating TCR&#x003b2; and TCR&#x003b3; in PBMC samples collected before treatment (day &#x02212;9) and after treatment (days +7 and +12) confirmed an increasing number, diversity and equitability of TCR clones after neoadjuvant ICI therapy (Fig. <xref rid="Fig5" ref-type="fig">5a</xref>).</p><p id="Par17">Peripheral blood cell subsets collected before treatment (day &#x02212;9) and after treatment (day +12) with neoadjuvant ICI therapy were analyzed using flow cytometry. The posttreatment sample contained substantially higher percentages of proliferating effector and memory (CD45+RA<sup>&#x02212;</sup>RO<sup>+</sup>) CD8<sup>+</sup>, CD4<sup>+</sup> T<sub>EM</sub> and CD4<sup>+</sup> T<sub>reg</sub> (Ki-67<sup>+</sup> fraction 34%, 50% and 81%, respectively; up from 3%, 2% and 11% in the pretreatment blood samples; Fig. <xref rid="Fig4" ref-type="fig">4b</xref>) cell subsets. The activation markers OX40 and MHC class II, and the cytotoxic marker GzmB, were each induced in circulating CD8<sup>+</sup>, CD4<sup>+</sup> and T<sub>reg</sub> subsets after neoadjuvant ICI therapy; PD-1 occupancy with nivolumab was also confirmed in these circulating T cells (Fig. <xref rid="Fig4" ref-type="fig">4b</xref>).</p><p id="Par18">The Olink proximity extension assay quantified 725 immuno-oncology-related proteins in serum samples collected before (day &#x02212;4) and after (days +7 and +12) treatment with neoadjuvant ICI therapy. Most proteins (681 of 725; 94%) showed minimal changes in response to immunotherapy (log<sub>2</sub> fold change after treatment relative to before treatment, between &#x02212;1 and +1). A distinct subset (44; 6%) proteins showed an increase or decrease of greater than twofold at days +7 and +12, compared with pretreatment protein levels (Extended Data Table <xref rid="Tab4" ref-type="table">4</xref>). These proteins were associated with T cell activation and cytokine and interleukin (IL) signaling; they included the drug targets LAG3 and PDCD1, several ILs (IL5, IL6, IL10, IL12), the C-X-C motif chemokine ligands CXCL9 and CXCL10, and IFN&#x003b3;.</p></sec><sec id="Sec6" sec-type="discussion"><title>Discussion</title><p id="Par19">A single dose of neoadjuvant nivolumab, ipilimumab and relatlimab increased the diversity, abundance and activation of TILs in the posttreatment tumor compared with the baseline tumor in newly diagnosed <italic>MGMT</italic> promoter unmethylated GBM. In other settings, activation and expansion of TILs and peripheral T cells have been associated with an ICI response<sup><xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref></sup>. While we observed features indicative of an ICI response, we cannot conclude that they predict clinical benefit for this patient. The binding of nivolumab to TILs confirms that intravenously administered ICIs can access the parenchyma of a primary brain tumor, whether via direct penetration or T cell-bound trafficking. Seventeen months after neoadjuvant combined (triplet) ICI, a maximal safe resection, adjuvant immunotherapies and a standard course of adjuvant radiotherapy, the patient has no definitive evidence of recurrence, which exceeds the median prognosis for this GBM when treated with chemoradiotherapy<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR6">6</xref></sup>.</p><p id="Par20">Our case highlights an opportunity to reexamine ICI for GBM with careful, data-driven and clinically informed optimization of neoadjuvant combination ICI in newly diagnosed GBM, without iatrogenic immunosuppression<sup><xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref></sup>. Our concern is that the negative ICI studies in GBM, using adjuvant single-agent ICI in pretreated patients with recurrent disease, may have missed a critical early &#x02018;window of opportunity&#x02019;<sup><xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR27">27</xref></sup> where ICI is ideally positioned to achieve a potentially curative response. Single-agent anti-PD-1 was not effective in patients with recurrent GBM who received prior chemotherapy and corticosteroids (~40% of patients at baseline were on prednisone at doses &#x0003c;10&#x02009;mg, probably reduced for &#x02018;trial eligibility&#x02019; in CheckMate 143) (refs. <sup><xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR28">28</xref></sup>). Likewise, concurrent anti-PD-1 and radiotherapy did not improve the outcomes of newly diagnosed patients with GBM with unmethylated <italic>MGMT</italic> promoter, where nearly 30% of patients were receiving corticosteroids at baseline<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. This scenario mirrors that of patients with melanoma brain metastasis, where those requiring corticosteroids for symptom management have a poorer response to ICIs than those not requiring steroids<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR29">29</xref></sup>. Importantly, single-agent anti-PD-1 has demonstrated activity in isolated cases with GBM associated with germline mismatch repair deficiency<sup><xref ref-type="bibr" rid="CR30">30</xref>,<xref ref-type="bibr" rid="CR31">31</xref></sup> and in newly diagnosed patients with <italic>MGMT</italic> methylated GBM treated in the neoadjuvant setting<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>.</p><p id="Par21">While single-agent anti-PD-1 shows limited benefit in most patient cohorts with GBM, combination ICIs target multiple independent steps in the cancer&#x02013;immunity cycle; when dosed optimally, they improved patient outcomes compared with anti-PD-1 alone in cancers such as melanoma<sup><xref ref-type="bibr" rid="CR4">4</xref></sup><sup>,<xref ref-type="bibr" rid="CR32">32</xref></sup><sup>,<xref ref-type="bibr" rid="CR33">33</xref></sup>. A small feasibility study (<italic>n</italic>&#x02009;=&#x02009;15, with nine patients unmethylated) reported a median OS of 19.3 months in newly diagnosed GBM treated with first-line adjuvant anti-PD-1 plus anti-CTLA-4, followed by standard radiotherapy<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>. One important barrier to investigating combination ICI is the induction of immune-related adverse events, which may affect quality of life, require immunosuppression that counteracts the activity of ICI or result in early cessation of ICI treatment. In our case study, combined (triplet) ICI was continued by personalizing the therapy to immune-related toxicity (delaying cycles and reducing combinations as necessary). Another perceived barrier to the use of combination ICI in brain tumors is the risk of cerebral edema; however, this was not observed in this case nor in patients with melanoma with active brain metastases who had no prior radiotherapy<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. The perceived risk of using ICIs in GBM may be because of the concern of exacerbating radiotherapy-induced inflammation<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>, especially given the doses and volumes of radiotherapy typically used in this tumor.</p><p id="Par22">There are limitations to this research, namely, that the clinical outcomes and biospecimens were derived from a single patient and technical replication was often not feasible because of the limited amount of sample. The generalizability of these findings may also be limited by the favorable early disease course, including a rapid interval between presentation and diagnosis, no tumor growth between the diagnostic and preoperative scans, good Eastern Cooperative Oncology Group Performance Status and limited tumor-associated edema (although there were some key poor prognostic factors, including an unmethylated <italic>MGMT</italic> promoter and incomplete resection because of the tumor&#x02019;s proximity to eloquent brain regions). If neoadjuvant ICI were trialed in newly diagnosed patients with GBM, the regimen would need to be rationally adapted to individual tumor and clinical factors.</p><p id="Par23">This case study suggests that neoadjuvant combination ICI can promote the infiltration, activation and expansion of tumor-specific T cells in newly diagnosed GBM. A regimen of upfront combination ICIs in newly diagnosed GBM is worthy of more thorough investigation before these agents can be excluded from the GBM treatment algorithm; a clinical trial, GIANT (trial registration no. <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT06816927">NCT06816927</ext-link>), is planned.</p></sec><sec id="Sec7"><title>Methods</title><sec id="Sec8"><title>Patient and ethics</title><p id="Par24">This research included a single 56-year-old white patient of male sex and gender. It was conducted in accordance with the Declaration of Helsinki (version 2024) and CAse REports guidelines, and with written informed consent of the patient. All drug therapy used in this study was obtained from Bristol Myers Squibb and submitted to the Therapeutic Goods Administration, Australia (Special Access Scheme, Category A). There was no participant compensation.</p><p id="Par25">Biospecimen samples were acquired with consent from the Sydney Brain Tumour Bank (no. 2019/ETH08929), the Melanoma Biospecimen Tissue Bank (no. HREC/11/RPAH/444) and the Macquarie University Cancer Biobank (no. HREC2793). Tumor sequencing was performed with consent from the Royal Melbourne Hospital Office for Research (no. HREC/61352/MH-2020 34).</p></sec><sec id="Sec9"><title>Next-generation sequencing and transcriptome analysis</title><p id="Par26">WGS was performed on patient-matched normal and tumor DNA on the Illumina NovaSeq 6000 platform using the Illumina TruSeq Nano DNA library preparation kit according to the manufacturer&#x02019;s instructions<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>. WGS analysis was performed using the Advanced Genomics Collaboration (TAGC) Clinical Genomics Analysis Platform to perform genome alignment (hg38) and variant calling using DRAGEN v.3.9 (refs. <sup><xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR40">40</xref></sup>), copy number variation using PURPLE v.2.51 (ref. <sup><xref ref-type="bibr" rid="CR41">41</xref></sup>) and structural rearrangement detection via the DRAGEN SV and breakpointinspector v.1.5 packages and prioritized using the simple_sv_annotation<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>. All workflows are written in the Common Workflow Language and are freely available under the MIT license in a version-controlled repository (<ext-link ext-link-type="uri" xlink:href="https://github.com/umccr/cwl-ica">https://github.com/umccr/cwl-ica</ext-link>).</p><p id="Par27">Total RNA samples were used as input for the NanoString IO 360 Panel and run on the nCounter Max/Flex Prep Station and Digital Analyzer<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>. Calculation of signature scores was performed using the singscore method from the raw read count table<sup><xref ref-type="bibr" rid="CR36">36</xref>,<xref ref-type="bibr" rid="CR37">37</xref></sup>.</p></sec><sec id="Sec10"><title>Flow cytometry analysis</title><p id="Par28">Flow cytometry staining was performed on viable cryopreserved tumor or PBMC samples<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. Samples were thawed and stained with fluorophore-conjugated antibodies against the following: CD45 (BUV737, clone HI30; 1/200 dilution, cat. no. 748719; research resouce ID (RRID): AB_2873123); CD45RA (BUV737, clone HI10; 1/100 dilution, cat. no. 564442; RRID: AB_2738810); CD45RO (BUV395, clone UCHL1; 1/20 dilution, cat. no. 564291; RRID: AB_2744410); CD3 (PE-CF594, clone UCHT1; 1/100 dilution, cat. no. 562280; RRID: AB_11153674); CD3 (BV786, clone UCHT1; 1/100 dilution, cat. no. 565491; RRID: AB_2739260); HLA-DR, HLA-DP, HLA-DQ (BUV395, clone Tu39; 1/200 dilution, cat. no. 740302; RRID: AB_2740041); CD8 (V500, clone SK1; 1/100 dilution, cat. no. 561617; RRID: AB_10896281); CD134 (OX40, PE-Cy7, clone Ber-ACT35; 1/20 dilution, cat. no. 563663; RRID: AB_2738358) (all were obtained from BD Biosciences); HLA-A, HLA-B, HLA-C (AF700, clone W6/32; 1/80 dilution, cat. no. 311438; RRID: AB_2566306); CD4 (AF700, clone A161A1; 1/40 dilution, cat. no. 357418; RRID: AB_2616933); HLA-DR (FITC, clone L243; 1/100 dilution, cat. no. 307604; RRID: AB_314682) (all from BioLegend); and CD223 (LAG3, PE, clone REA351; 1/11 dilution, cat. no. 130-105-452, Miltenyi Biotech; RRID: AB_2656407). Nonspecific staining was blocked with Fc block (clone Fc1, 1/200 dilution, cat. no. 564220, BD Biosciences; RRID: AB_2728082). For the detection of T cell-bound nivolumab, cells were incubated with human IgG4Fc (PE, clone HP6025; 1/100 dilution, cat. no. 9200-09, Southern Biotech; RRID: AB_2796693). For direct PD-1 detection, cells were stained with CD279 (PD-1, BV421, clone EH12.1; 1/50 dilution; cat. no. 562516, BD Biosciences; RRID: AB_11153482). Cell viability was determined by staining cells with LIVE/DEAD near-infrared fixable dye (cat. no. L34976, Thermo Fisher Scientific).</p><p id="Par29">After cell surface staining, cells were fixed and permeabilized using the eBioscience Transcription Factor Buffer Kit (cat. no. 00-5523-00, Thermo Fisher Scientific) and stained with the following antibodies plus Fc block in permeabilization buffer: FOXP3 (PE-CF594, clone 236A/E7; 1/20 dilution, cat. no. 563955; RRID: AB_2738507); GFAP (AF488, clone 1B4; 1/20 dilution, cat. no. 560297; RRID: AB_1645350); GzmB (AF700, clone GB1; 1/100 dilution, cat. no. 560213; RRID: AB_1645453); SOX2 (PE, clone O30-678; 1/100 dilution, cat. no. 562195; RRID: AB_10895118) (all from BD Biosciences); CD152 (CTLA-4, APC, clone 14D3; 1/20 dilution, cat. no. 17-1529-42; RRID: AB_2688162); Ki-67 (APC, clone 20Raj1; 1/150 dilution, cat. no. 17-5699-42; RRID: AB_2573218) (both from Thermo Fisher Scientific). Samples were washed extensively and immediately acquired on a BD LSRFortessa X20 flow cytometer (BD Biosciences). Samples were analyzed with the FlowJo software v.10.8 (BD Biosciences).</p></sec><sec id="Sec11"><title>PhenoCycler&#x02013;Fusion tissue imaging and analysis</title><p id="Par30">Antibodies targeting tumor and non-tumor cells in the TME were conjugated to short DNA oligonucleotides and titrated according to the manufacturer&#x02019;s instructions (Akoya Biosciences)<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. Antigens shown in this study include the following: CD14 (AKYP0079, 1/200 dilution, Akoya Biosciences), CD11c (AKYP0051, 1/400 dilution, Akoya Biosciences), CD141 (AKP0124, 1/200 dilution, Akoya Biosciences), CD3 (AKYP0062, 1/200 dilution, Akoya Biosciences), CD8 (AKYP0028, 1/200 dilution, Akoya Biosciences), CD4 (AKYP0048, 1/200 dilution, Akoya Biosciences), GzmB (AKYP0086, 1/100 dilution, Akoya Biosciences), FOXP3 (AKYP0086, 1/100 dilution, Akoya Biosciences) and S100B (1/200 dilution, cat. no. 42397, Cell Signaling Technology). Initial T cell quantification was performed using the HALO AI v.3.6 image analysis platform with default artificial intelligence-based cell sequencing and manual gating of T cell phenotypes. Subsequent broad immunophenotyping was performed with cell segmentation in StarDist using the DAPI channel (cytoplasm segmentation was estimated using a morphological dilation of 5&#x02009;&#x000b5;m); cell phenotyping for CD4<sup>+</sup> and CD8<sup>+</sup> T cells was performed using the machine learning classifier in QuPath v.0.4.4 (ref. <sup><xref ref-type="bibr" rid="CR44">44</xref></sup>). Cell neighborhood enrichment analysis was performed using a graph-based connectivity algorithm with the squidpy Python package<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. Cell proximity in spatial neighborhoods was quantified with a permutation-based test (1,000 default) by comparing the spatial location of cell types and their relative distances.</p></sec><sec id="Sec12"><title>TCR pan-clonality assay</title><p id="Par31">DNA target amplification (200&#x02009;ng genomic DNA input), partial digestion, barcoding of amplicons and purification were performed according to the manufacturer&#x02019;s protocol (Oncomine Human Immune Repertoire user guide for TCR pan-clonality assay, Thermo Fisher Scientific). The barcoding set consisted of the IonTorrent Dual Barcode Kit 1&#x02013;96 (Thermo Fisher Scientific). Target amplification was for 31 cycles.</p><p id="Par32">Purified libraries were quantified with quantitative PCR (qPCR) using an Ion Library TaqMan Quantitation Kit (Thermo Fisher Scientific) according to the Oncomine Human Immune Repertoire user guide. A 1/100 dilution of each sample library was analyzed in each case. qPCR was performed using a QuantStudio 7 Pro qPCR system (Thermo Fisher Scientific) in standard run mode (Oncomine Human Immune Repertoire user guide). Individual barcoded libraries were diluted to a final concentration of 50&#x02009;pM in nuclease-free water using Eppendorf DNA LoBind microcentrifuge tubes (Sigma-Aldrich). For each sequencing chip, equal volumes (5&#x02009;&#x000b5;l) of 12 diluted library samples were combined on ice. Subsequently, 25&#x02009;&#x000b5;l of the pooled libraries were used for template preparation and chip loading.</p><p id="Par33">The sequencing workflow consisted of template preparation and sequencing chip loading on an Ion Chef instrument (Thermo Fisher Scientific), sequencing on an Ion GeneStudio S5 plus system (Thermo Fisher Scientific) followed by data analysis. Planned sequencing runs were based on the Oncomine TCR Pan-Clonality Assay using the Torrent Suite software v.5.18.1. The kits used for each planned sequencing run were an Ion 550 Kit&#x02013;Chef, Ion S5 Sequencing Kit and Ion 550 chip (Thermo Fisher Scientific). Sequencing data were automatically uploaded to the Ion reporter software v.5.18.4 for analysis using the Oncomine TCR Beta-SR and Gamma-SR&#x02013;w1.4&#x02013;DNA Single Sample workflow. Multi-sample analysis was based on join CDR3 nt.</p><p id="Par34">Clonotypes were defined using V, J and CDR3 amino acid sequences from the TCR&#x003b2; and TCR&#x003b3; clone summaries from Thermo Fisher Scientific Ion Torrent targeted next-generation sequencing assay. Nonproductive clonotypes, based on the &#x02018;functionality&#x02019; field, were excluded from the analysis. The productive clonotype frequency was calculated based on the total number of reads for a clonotype divided by the total number of productive reads in the sample. Clonotype diversity Shannon entropy (<italic>H</italic>) was calculated based on the clonotype abundances in each sample using <italic>H</italic>&#x02009;=&#x02009;&#x02212;<italic>&#x003a3;pi</italic>&#x02009;&#x000d7;&#x02009;ln(<italic>pi</italic>), where <italic>pi</italic> is the proportion of sequence <italic>i</italic> relative to the total N sequences<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>. Maximum Shannon diversity was calculated as ln(total clonotypes). The Shannon equitability or evenness was calculated as <italic>H</italic>/(max diversity).</p></sec><sec id="Sec13"><title>Distribution of clonotypes in each sample</title><p id="Par35">Clonotypes were ranked according to their frequency, from largest to smallest, using min_rank from the dplyr R package (<ext-link ext-link-type="uri" xlink:href="https://dplyr.tidyverse.org">https://dplyr.tidyverse.org</ext-link>)<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>. The min_rank approach gives every tie the same (smallest) value. The cumulative frequency for the ranked clonotypes in each sample was calculated using the cumsum function from base R. Data analysis was performed in R v.4.3.0 (21 April 2023 release) using RStudio v.4.3.0 (<ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/bin/windows/base/old/4.3.0/">https://cran.r-project.org/bin/windows/base/old/4.3.0/</ext-link>, ref. <sup><xref ref-type="bibr" rid="CR48">48</xref></sup>) with the following R packages: tidyverse v.2.0.0 (ref. <sup><xref ref-type="bibr" rid="CR49">49</xref></sup>); ggpubr (<ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/ggpubr/index.html">https://cran.r-project.org/web/packages/ggpubr/index.html</ext-link>); ggsci v.3.0.0 (<ext-link ext-link-type="uri" xlink:href="https://github.com/nanxstats/ggsci">https://github.com/nanxstats/ggsci</ext-link>); lemon v.0.4.9 (<ext-link ext-link-type="uri" xlink:href="https://github.com/stefanedwards/lemon">https://github.com/stefanedwards/lemon</ext-link>); and UpSetR v.1.4.0 (<ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=UpSetR">https://CRAN.R-project.org/package=UpSetR</ext-link>).</p></sec><sec id="Sec14"><title>Proximity extension assay</title><p id="Par36">Plasma samples collected before (day &#x02212;4) and after treatment (days +7 and +12) were analyzed using the proximity extension assay at the Olink Proteomics facility, Uppsala, Sweden. In total, 725 immuno-oncology-related protein biomarkers (Olink Explore 384 Inflammation, Olink Explore 384 Oncology (<ext-link ext-link-type="uri" xlink:href="https://olink.com/">www.olink.com</ext-link>)) were measured and reported as normalized protein expression values, which is an arbitrary unit on a log<sub>2</sub> scale, where a higher value corresponds to higher protein expression.</p></sec><sec id="Sec15"><title>CTC analysis</title><p id="Par37">A total of 7.5&#x02009;ml whole-blood samples were processed using the AccuCyte-CyteFinder platform (RareCyte)<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>. Nucleated blood cells were isolated using AccuCyte (RareCyte) and spread onto eight SuperFrost Plus slides (Thermo Fisher Scientific). Slides were immunofluorescently stained on the Autostainer Link 48 (Agilent Technologies) using the following: anti-GFAP (AF488; cat. no. 560297, Becton Dickinson), anti-EGFR (PE; cat. no. FAB9577P, R&#x00026;D Systems), anti-CD45 (AF750; cat. no. NBP1-79127AF750, Novus Biologicals), anti-CD66b (AF750; cat. no. FAB42462, R&#x00026;D Systems) antibodies and a nuclear DAPI dye (Thermo Fisher Scientific). Slides were then scanned on the CyteFinder HT (RareCyte) digital immunofluorescence microscope at &#x000d7;10 magnification, with the following exposure times: 0.05&#x02009;s (DAPI); 0.01&#x02009;s (GFAP); 0.1&#x02009;s (EGFR); and 0.1&#x02009;s (CD45/CD66b). Image files were analyzed using an automated software and presented to the reviewer for CTC confirmation (CyteMapper, RareCyte). A CTC was defined as positive for DAPI and GFAP, and negative for CD45/CD66b (mean fluorescence intensity cutoff&#x02009;=&#x02009;15).</p></sec><sec id="Sec16"><title>Reporting summary</title><p id="Par38">Further information on research design is available in the <xref rid="MOESM2" ref-type="media">Nature Portfolio Reporting Summary</xref> linked to this article.</p></sec></sec><sec id="Sec17" sec-type="materials|methods"><title>Online content</title><p id="Par39">Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at 10.1038/s41591-025-03512-1.</p></sec><sec id="Sec19" sec-type="supplementary-material"><title>Supplementary information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41591_2025_3512_MOESM1_ESM.pdf"><label>Supplementary Information</label><caption><p>Supplementary Results 1&#x02013;3.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="41591_2025_3512_MOESM2_ESM.pdf"><caption><p>Reporting Summary</p></caption></media></supplementary-material>
</p></sec><sec id="Sec20" sec-type="supplementary-material"><title>Source data</title><p>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="41591_2025_3512_MOESM3_ESM.xlsx"><label>Source Data Figs. 2&#x02013;5 and Extended Data Figs. 1&#x02013;3</label><caption><p>Statistical source data</p></caption></media></supplementary-material>
</p></sec></body><back><app-group><app id="App1"><sec id="Sec18"><title>Extended data</title><p id="Par44">
<fig id="Fig6"><label>Extended Data Fig. 1</label><caption><title>Identification of circulating tumor cells.</title><p>Representative region of whole-slide immunofluorescence showing circulating tumor cell (CTC, boxed) identified in a GBM patient. Cells were stained for GFAP (green), EGFR (yellow), CD45/CD66b (white) and nuclear DAPI (blue). Magnification, 40X. Sample collected pretreatment (day &#x02013;9). 7.5&#x02009;mL peripheral blood was processed on the AccuCyte-CyteFinder platform (RareCyte). Nucleated blood cells were spread on 8 slides. Slides were stained using DAKO autostainer and the whole slide was imaged and analyzed by CyteMapper software for DAPI&#x02009;<sup>+</sup>&#x02009;GFAP&#x02009;<sup>+</sup>&#x02009;EGFR<sup>&#x02009;+&#x02009;/&#x02212;</sup> CD45/CD66b<sup>&#x02212;</sup> cells with user verification. Scale bars = 100 &#x003bc;m.</p><p>
<xref rid="MOESM3" ref-type="media">Source data</xref>
</p></caption><graphic position="anchor" xlink:href="41591_2025_3512_Fig6_ESM" id="d33e1647"/></fig>
</p><p id="Par45">
<fig id="Fig7"><label>Extended Data Fig. 2</label><caption><title>Evaluation of CD3+ immune cells in longitudinal GBM biopsy and surgical specimens in A) the ICI-treated left temporal GBM and B) an untreated right frontal GBM.</title><p><bold>a</bold>) Representative region of whole-slide immunohistochemistry images of pretreatment (day &#x02013;4) and posttreatment (day +13) GBM specimens for CD3<sup>+</sup>&#x02009;T cells across left temporal and amygdala sections. Percentage CD3<sup>+</sup>&#x02009;T cell content is shown and was quantitated from over 1,300 cells in each tissue specimen using QuPath. Representative regions were taken from areas of increased tumor cellularity. <bold>b</bold>) Representative region of whole-slide immunohistochemistry images showing CD3<sup>+</sup>&#x02009;T cell infiltration in biopsy and resection specimens from a 66-year-old male with right frontal lobe GBM. The patient underwent an initial diagnostic biopsy, followed by maximal tumor resection 14 days later. Percentage CD3<sup>+</sup>&#x02009;T cell content is shown and was quantitated from over 1,200 cells in each tissue specimen using QuPath. Representative regions were taken from areas of increased tumor cellularity. Scale bars = 100&#x02009;&#x003bc;m.</p><p>
<xref rid="MOESM3" ref-type="media">Source data</xref>
</p></caption><graphic position="anchor" xlink:href="41591_2025_3512_Fig7_ESM" id="d33e1677"/></fig>
</p><p id="Par46">
<fig id="Fig8"><label>Extended Data Fig. 3</label><caption><title>Frequency of lymphocyte subsets in primary GBM.</title><p>Heat map showing frequency of lymphocyte subsets in primary GBM tumor dissociates (n&#x02009;=&#x02009;13), including the pretreatment and posttreatment GBM tumor dissociates (highlighted in red). Samples are ranked according to CD3<sup>+</sup>&#x02009;T cell content. T cell subsets (CD3<sup>+</sup>&#x02009;T cells, CD4<sup>+</sup>FOXP3<sup>+</sup> regulatory T cells (Tregs), CD4<sup>+</sup>FOXP3<sup>-</sup> effector memory T cells (Tem) and CD8<sup>+</sup>&#x02009;T cells) are shown as percentage of total CD45<sup>+</sup> cells. CD45<sup>+</sup> lymphocytes are shown as percentage of viable cells.</p><p>
<xref rid="MOESM3" ref-type="media">Source data</xref>
</p></caption><graphic position="anchor" xlink:href="41591_2025_3512_Fig8_ESM" id="d33e1713"/></fig>
</p><p id="Par47">
<table-wrap id="Tab1"><label>Extended Data Table 1</label><caption><p>Neoadjuvant immune checkpoint inhibitor trials in glioblastoma</p></caption><graphic position="anchor" xlink:href="41591_2025_3512_Tab1_ESM" id="d33e1723"><!--Dupe caption: Neoadjuvant immune checkpoint inhibitor trials in glioblastoma--></graphic></table-wrap>
</p><p id="Par48">
<table-wrap id="Tab2"><label>Extended Data Table 2</label><caption><p>Whole-genome sequencing summary of the pretreatment specimen</p></caption><graphic position="anchor" xlink:href="41591_2025_3512_Tab2_ESM" id="d33e1736"><!--Dupe caption: Whole-genome sequencing summary of the pretreatment specimen--></graphic></table-wrap>
</p><p id="Par49">
<table-wrap id="Tab3"><label>Extended Data Table 3</label><caption><p>Chronological details of the treatment schedule</p></caption><graphic position="anchor" xlink:href="41591_2025_3512_Tab3_ESM" id="d33e1749"><!--Dupe caption: Chronological details of the treatment schedule--></graphic></table-wrap>
</p><p id="Par50">
<table-wrap id="Tab4"><label>Extended Data Table 4</label><caption><p>Normalized Olink proteomics plasma data expressed as normalized expression units on a log<sub>2</sub> scale</p></caption><graphic position="anchor" xlink:href="41591_2025_3512_Tab4_ESM" id="d33e1765"><!--Dupe caption: Normalized Olink proteomics plasma data expressed as normalized expression units on a log2 scale--></graphic></table-wrap>
</p></sec></app></app-group><fn-group><fn><p><bold>Publisher&#x02019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p><bold>Change history</bold></p><p>3/8/2025</p><p id="Par1">In the version of this article initially published, the second and third labels on the y axis of the &#x0201c;Posttreament&#x0201d; heatmap in Fig. 2b were out of order and are now amended to match the &#x0201c;Pretreatment&#x0201d; labels in the HTML and PDF versions of the article.</p></fn><fn><p><bold>Change history</bold></p><p>4/4/2025</p><p id="Par2">In the version of the article initially published, the sentence "We thank K. Alexander and the Sydney Brain Tumour Bank at the Chris O&#x02019;Brien Lifehouse and Royal Prince Alfred Hospital for providing tissue and plasma specimens" was missing from the Acknowledgements section and has now been added to the HTML and PDF versions of the article.</p></fn></fn-group><sec><sec id="FPar1"><title>Extended data</title><p id="Par40">is available for this paper at 10.1038/s41591-025-03512-1.</p></sec><sec id="FPar2" sec-type="supplementary-material"><title>Supplementary information</title><p id="Par41">The online version contains supplementary material available at 10.1038/s41591-025-03512-1.</p></sec></sec><ack><title>Acknowledgements</title><p>We thank A. Bastian for antibody optimization and blood sample processing for the CTC analysis, K. Jackson for her expertise with TCR analysis and B. Pedersen for expertise with the flow cytometry experiments. We thank K. Pham, O. Hofmann and the Collaborative Centre for Genomic Cancer Medicine for performing the WGS analysis and J. Checkley and the Macquarie University Cancer Biobank for providing the GBM tumor dissociates. We thank K. Alexander and the Sydney Brain Tumour Bank at the Chris O&#x02019;Brien Lifehouse and Royal Prince Alfred Hospital for providing tissue and plasma specimens. WGS was performed as part of the COLUMN initiative. The authors received no specific funding for this work. Investigators were supported by Melanoma Institute Australia (C.Q.), National Health and Medical Research Council Investigator grants (to G.V.L., R.A.S., T.G.P., A.M.M. and J.S.W.), Cancer Institute NSW grants (no. 2020/ECF1153 to C.Q.; no. 2020/ECF1244 to T.N.G.; no. 2021/CBG0002 to D.Y.), NSW Health Early-Mid Career grants (to C.Q.), the University of Sydney Medical School Foundation (G.V.L.), the CLEARbridge Foundation (R.J.D.), N. and H. Moore (A.M.M.) and PhD scholarships from the University of Sydney and Melanoma Institute Australia (X.B.). We thank Bristol Myers Squibb for providing the study drugs nivolumab, relatlimab and ipilimumab. Bristol Myers Squibb had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>G.V.L. conceived and designed the study treatment and biospecimen collection, recruited the patient, coordinated the study treatment and designed and interpreted the scientific experiments and analyses. G.V.L. was responsible for the administration, clinical care and monitoring of the immunotherapy and vaccine treatment, and for monitoring the response. H.R. provided scientific oversight, designed the scientific experiments and analyses, generated the data and performed the data analysis and interpretation. E.S., Y.M., I.P.d.S., X.B., C.Q., I.A.V., T.G.P., T.N.G., D.Y., J.E.J.R., R.J.D., S.M.G., J.H.A.V., U.P. and J.S.W. designed the scientific experiments, generated the data and performed the data analysis. G.V.L., J.S.W. and H.R. provided project management and data storage and consolidation. B.S. performed all neurosurgical interventions and advised on timing of surgery. M.B. was responsible for the administration of radiotherapy and for monitoring the response. H.W. was responsible for the neuro-oncology clinical care and for monitoring the response. J.D. and E.H. reviewed and interpreted the radiology data. N.C. and M.G. coordinated and performed the biospecimen collection, processing and storage, and provided operational support. L.S. and M.E.B. performed the pathological processing and analysis. R.V.R. and R.A.S. reviewed the pathology specimens. I.P.d.S., A.M.M., M.S.C., B.N., D.A.R., D.M.A. and M.K. provided clinical support. K.A.P. performed the literature review, consolidated the data and aided in the interpretation of the results. G.V.L., H.R. and K.A.P. collaboratively wrote all the manuscript drafts. All authors reviewed the results and the manuscript and approved the final version.</p></notes><notes notes-type="peer-review"><title>Peer review</title><sec id="FPar3"><title>Peer review information</title><p id="Par42"><italic>Nature Medicine</italic> thanks the anonymous reviewers for their contribution to the peer review of this work. Primary Handling Editor: Ulrike Harjes, in collaboration with the <italic>Nature Medicine</italic> team.</p></sec></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by the University of Sydney.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Requests for data access will be reviewed by the senior authors. Applicants can expect a response within 2 weeks of submission. Data will be provided under the following conditions: (1) the research must have received ethical approval from a recognized ethics review board; (2) the request must align with the scientific aims and goals of the dataset; (3) the requesting team must demonstrate the ability to handle the data securely and responsibly; (4) a formal data usage agreement must be signed, ensuring that the data will not be used for commercial purposes and will not be shared with unauthorized parties. <xref ref-type="sec" rid="Sec20">Source data</xref> are provided with this paper.</p></notes><notes id="FPar4" notes-type="COI-statement"><title>Competing interests</title><p id="Par43">G.V.L. is consultant adviser for Agenus, Amgen, Array Biopharma, AstraZeneca, Bayer, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Evaxion, Hexal AG (a Sandoz Company), Highlight Therapeutics, IOBiotech, Immunocore, Innovent Biologics USA, Merck Sharpe &#x00026; Dohme, Novartis, PHMR Ltd, Pierre Fabre and Regeneron. R.V.R. has received an honorarium from Merck Sharpe &#x00026; Dohme. M.S.C. has served on advisory boards or as a consultant for Amgen, Bristol Myers Squibb, Eisai, Ideaya, Merck Sharpe &#x00026; Dohme, Nektar, Novartis, Oncosec, Pierre Fabre, Qbiotics, Regeneron, Roche, Merck KGaA and Sanofi, and received honoraria from Bristol Myers Squibb, Merck Sharpe &#x00026; Dohme and Novartis. D.E.G. has served on advisory boards for Amgen and received honoraria from Bristol Myers Squibb and Merck Sharpe &#x00026; Dohme. J.E.J.R. reports advisory roles for the Gene Technology Technical Advisory Committee, the Office of the Gene Technology Regulator, the Australian Government and the Human Research Ethics Committee of Genea. J.E.J.R. also reports honoraria, speaker fees or advisory roles for SPARK Therapeutics, Cynata and Pfizer; shares in Woke Pharmaceutical; is a nonexecutive director of Kennerton Capital; is a cofounder of AAVec Bio; and a consultant role for RareCyteand, with stocks in lieu. A.M.M. has served on advisory boards for Bristol Myers Squibb, Merck Sharpe &#x00026; Dohme, Novartis, Roche, Pierre Fabre and QBiotics. I.P.d.S. declares honoraria, speaker fees or advisory roles for Pierre Fabre, Merck Sharpe &#x00026; Dohme, Roche, Novartis and Bristol Myers Squibb, and has served as consultant on advisory boards for Merck Sharpe &#x00026; Dohme. D.A.R. has received honoraria for serving on advisory boards or as a consultant for Agenus, Avita Biomedical, Bayer, Blue Rock Therapeutics, Boston Biomedical, Boehringer Ingelheim, Bristol Myers Squibb, CeCava, Chimeric Therapeutics, Deciphera, Ellipses Pharma, EMD Serono, Genentech/Roche, Imvax, Inovio, Medicenna Biopharma, Merck Sharpe &#x00026; Dohme, Merck KGaA, Monteris, Novartis, Oncorus, Oxigene, Regeneron and Taiho Oncology. He has stocks in AnHeart Therapeutics and Bionaut Labs. Laboratory research support for his work has been paid to the Dana-Farber Cancer Institute by Enterome, NeoTX Ltd (240K) and Ashvattha Therapeutics (119K). M.K. reports grants or contracts from Bristol Myers Squibb, AbbVie, BioNTech, CNS Pharmaceuticals, Daiichi Sankyo, Immorna Therapeutics, Immvira Therapeutics, JAX lab for genomic research and Personalis; he has received consulting fees from AnHeart Therapeutics, Berg Pharma, George Clinical, Manarini Stemline and Servier; he has received honoraria from GlaxoSmithKline; and is on a data safety monitoring board for BPGbio. R.A.S. has received fees for professional services from SkylineDx, IO Biotech, MetaOptima Technology, Roche, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp &#x00026; Dohme, NeraCare, Amgen, Bristol Myers Squibb, Myriad Genetics and GlaxoSmithKline. R.A.S. is both the subject and an author of this study. The other authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Louis</surname><given-names>DN</given-names></name><etal/></person-group><article-title>The 2021 WHO Classification of Tumors of the Central Nervous System: a summary</article-title><source>Neuro Oncol.</source><year>2021</year><volume>23</volume><fpage>1231</fpage><lpage>1251</lpage><pub-id pub-id-type="pmid">34185076</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Louis, D. N. et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. <italic>Neuro Oncol.</italic><bold>23</bold>, 1231&#x02013;1251 (2021).<pub-id pub-id-type="pmid">34185076</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Stupp</surname><given-names>R</given-names></name><etal/></person-group><article-title>Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma</article-title><source>N. Engl. J. Med.</source><year>2005</year><volume>352</volume><fpage>987</fpage><lpage>996</lpage><pub-id pub-id-type="pmid">15758009</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. <italic>N. Engl. J. Med.</italic><bold>352</bold>, 987&#x02013;996 (2005).<pub-id pub-id-type="pmid">15758009</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Ostrom</surname><given-names>QT</given-names></name><etal/></person-group><article-title>National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States</article-title><source>Neuro Oncol.</source><year>2023</year><volume>25</volume><fpage>799</fpage><lpage>807</lpage><pub-id pub-id-type="pmid">35994777</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Ostrom, Q. T. et al. National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States. <italic>Neuro Oncol.</italic><bold>25</bold>, 799&#x02013;807 (2023).<pub-id pub-id-type="pmid">35994777</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Wolchok</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma</article-title><source>N. Engl. J. Med.</source><year>2025</year><volume>392</volume><fpage>11</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">39282897</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Wolchok, J. D. et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. <italic>N. Engl. J. Med.</italic><bold>392</bold>, 11&#x02013;22 (2025).<pub-id pub-id-type="pmid">39282897</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Sim</surname><given-names>H-W</given-names></name><etal/></person-group><article-title>NUTMEG: a randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma</article-title><source>Neurooncol. Adv.</source><year>2023</year><volume>5</volume><fpage>vdad124</fpage><pub-id pub-id-type="pmid">37841696</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Sim, H.-W. et al. NUTMEG: a randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma. <italic>Neurooncol. Adv.</italic><bold>5</bold>, vdad124 (2023).<pub-id pub-id-type="pmid">37841696</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Omuro</surname><given-names>A</given-names></name><etal/></person-group><article-title>Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial</article-title><source>Neuro Oncol.</source><year>2023</year><volume>25</volume><fpage>123</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">35419607</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Omuro, A. et al. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial. <italic>Neuro Oncol.</italic><bold>25</bold>, 123&#x02013;134 (2023).<pub-id pub-id-type="pmid">35419607</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>M</given-names></name><etal/></person-group><article-title>Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter</article-title><source>Neuro Oncol.</source><year>2022</year><volume>24</volume><fpage>1935</fpage><lpage>1949</lpage><pub-id pub-id-type="pmid">35511454</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Lim, M. et al. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. <italic>Neuro Oncol.</italic><bold>24</bold>, 1935&#x02013;1949 (2022).<pub-id pub-id-type="pmid">35511454</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Aaroe</surname><given-names>A</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Puduvalli</surname><given-names>VK</given-names></name></person-group><article-title>Tumor microenvironment in glioblastoma: current and emerging concepts</article-title><source>Neurooncol. Adv.</source><year>2023</year><volume>5</volume><fpage>vdad009</fpage><pub-id pub-id-type="pmid">36968288</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Sharma, P., Aaroe, A., Liang, J. &#x00026; Puduvalli, V. K. Tumor microenvironment in glioblastoma: current and emerging concepts. <italic>Neurooncol. Adv.</italic><bold>5</bold>, vdad009 (2023).<pub-id pub-id-type="pmid">36968288</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Pombo Antunes</surname><given-names>AR</given-names></name><etal/></person-group><article-title>Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies</article-title><source>eLife</source><year>2020</year><volume>9</volume><fpage>52176</fpage></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Pombo Antunes, A. R. et al. Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies. <italic>eLife</italic><bold>9</bold>, 52176 (2020).</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>AH</given-names></name><etal/></person-group><article-title>Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>6938</fpage><pub-id pub-id-type="pmid">34836966</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Lee, A. H. et al. Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. <italic>Nat. Commun.</italic><bold>12</bold>, 6938 (2021).<pub-id pub-id-type="pmid">34836966</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Cloughesy</surname><given-names>TF</given-names></name><etal/></person-group><article-title>Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma</article-title><source>Nat. Med.</source><year>2019</year><volume>25</volume><fpage>477</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">30742122</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Cloughesy, T. F. et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. <italic>Nat. Med.</italic><bold>25</bold>, 477&#x02013;486 (2019).<pub-id pub-id-type="pmid">30742122</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Schalper</surname><given-names>KA</given-names></name><etal/></person-group><article-title>Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma</article-title><source>Nat. Med.</source><year>2019</year><volume>25</volume><fpage>470</fpage><lpage>476</lpage><pub-id pub-id-type="pmid">30742120</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Schalper, K. A. et al. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. <italic>Nat. Med.</italic><bold>25</bold>, 470&#x02013;476 (2019).<pub-id pub-id-type="pmid">30742120</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>de Groot</surname><given-names>J</given-names></name><etal/></person-group><article-title>Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages</article-title><source>Neuro Oncol.</source><year>2020</year><volume>22</volume><fpage>539</fpage><lpage>549</lpage><pub-id pub-id-type="pmid">31755915</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">de Groot, J. et al. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. <italic>Neuro Oncol.</italic><bold>22</bold>, 539&#x02013;549 (2020).<pub-id pub-id-type="pmid">31755915</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Dobersalske</surname><given-names>C</given-names></name><etal/></person-group><article-title>Cranioencephalic functional lymphoid units in glioblastoma</article-title><source>Nat. Med.</source><year>2024</year><volume>30</volume><fpage>2947</fpage><lpage>2956</lpage><pub-id pub-id-type="pmid">39085419</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Dobersalske, C. et al. Cranioencephalic functional lymphoid units in glioblastoma. <italic>Nat. Med.</italic><bold>30</bold>, 2947&#x02013;2956 (2024).<pub-id pub-id-type="pmid">39085419</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Ascierto</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Efficacy and safety of triplet nivolumab, relatlimab, and ipilimumab (NIVO + RELA + IPI) in advanced melanoma: results from RELATIVITY-048</article-title><source>J. Clin. Oncol.</source><year>2024</year><volume>42</volume><fpage>9504</fpage></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Ascierto, P. A. et al. Efficacy and safety of triplet nivolumab, relatlimab, and ipilimumab (NIVO + RELA + IPI) in advanced melanoma: results from RELATIVITY-048. <italic>J. Clin. Oncol.</italic><bold>42</bold>, 9504 (2024).</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Gide</surname><given-names>TN</given-names></name><etal/></person-group><article-title>Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy</article-title><source>Cancer Cell</source><year>2019</year><volume>35</volume><fpage>238</fpage><lpage>255</lpage><pub-id pub-id-type="pmid">30753825</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Gide, T. N. et al. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy. <italic>Cancer Cell</italic><bold>35</bold>, 238&#x02013;255 (2019).<pub-id pub-id-type="pmid">30753825</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Rozeman</surname><given-names>EA</given-names></name><etal/></person-group><article-title>Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma</article-title><source>Nat. Med.</source><year>2021</year><volume>27</volume><fpage>256</fpage><lpage>263</lpage><pub-id pub-id-type="pmid">33558721</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Rozeman, E. A. et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. <italic>Nat. Med.</italic><bold>27</bold>, 256&#x02013;263 (2021).<pub-id pub-id-type="pmid">33558721</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Long, G. V. et al. Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised phase 2 study. <italic>Lancet Oncol.</italic>10.1016/S1470-2045(24)00735-6 (2025).</mixed-citation></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Pires da Silva</surname><given-names>I</given-names></name><etal/></person-group><article-title>Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study</article-title><source>Lancet Oncol.</source><year>2021</year><volume>22</volume><fpage>836</fpage><lpage>847</lpage><pub-id pub-id-type="pmid">33989557</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Pires da Silva, I. et al. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. <italic>Lancet Oncol.</italic><bold>22</bold>, 836&#x02013;847 (2021).<pub-id pub-id-type="pmid">33989557</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Musca</surname><given-names>B</given-names></name><etal/></person-group><article-title>The immune cell landscape of glioblastoma patients highlights a myeloid-enriched and immune suppressed microenvironment compared to metastatic brain tumors</article-title><source>Front. Immunol.</source><year>2023</year><volume>14</volume><fpage>1236824</fpage><pub-id pub-id-type="pmid">37936683</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Musca, B. et al. The immune cell landscape of glioblastoma patients highlights a myeloid-enriched and immune suppressed microenvironment compared to metastatic brain tumors. <italic>Front. Immunol.</italic><bold>14</bold>, 1236824 (2023).<pub-id pub-id-type="pmid">37936683</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Pan-tumor pathologic scoring of response to PD-(L)1 blockade</article-title><source>Clin. Cancer Res.</source><year>2020</year><volume>26</volume><fpage>545</fpage><lpage>551</lpage><pub-id pub-id-type="pmid">31672770</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Stein, J. E. et al. Pan-tumor pathologic scoring of response to PD-(L)1 blockade. <italic>Clin. Cancer Res.</italic><bold>26</bold>, 545&#x02013;551 (2020).<pub-id pub-id-type="pmid">31672770</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response</article-title><source>Ann. Oncol.</source><year>2019</year><volume>30</volume><fpage>589</fpage><lpage>596</lpage><pub-id pub-id-type="pmid">30689736</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Stein, J. E. et al. Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response. <italic>Ann. Oncol.</italic><bold>30</bold>, 589&#x02013;596 (2019).<pub-id pub-id-type="pmid">30689736</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Cottrell</surname><given-names>TR</given-names></name><etal/></person-group><article-title>Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)</article-title><source>Ann. Oncol.</source><year>2018</year><volume>29</volume><fpage>1853</fpage><lpage>1860</lpage><pub-id pub-id-type="pmid">29982279</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Cottrell, T. R. et al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). <italic>Ann. Oncol.</italic><bold>29</bold>, 1853&#x02013;1860 (2018).<pub-id pub-id-type="pmid">29982279</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Menzies</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)</article-title><source>Nat. Med.</source><year>2021</year><volume>27</volume><fpage>301</fpage><lpage>309</lpage><pub-id pub-id-type="pmid">33558722</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Menzies, A. M. et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). <italic>Nat. Med.</italic><bold>27</bold>, 301&#x02013;309 (2021).<pub-id pub-id-type="pmid">33558722</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>SP</given-names></name><etal/></person-group><article-title>Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma</article-title><source>N. Engl. J. Med.</source><year>2023</year><volume>388</volume><fpage>813</fpage><lpage>823</lpage><pub-id pub-id-type="pmid">36856617</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Patel, S. P. et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. <italic>N. Engl. J. Med.</italic><bold>388</bold>, 813&#x02013;823 (2023).<pub-id pub-id-type="pmid">36856617</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>K</given-names></name><etal/></person-group><article-title>Correcting the drug development paradigm for glioblastoma requires serial tissue sampling</article-title><source>Nat. Med.</source><year>2023</year><volume>29</volume><fpage>2402</fpage><lpage>2405</lpage><pub-id pub-id-type="pmid">37488293</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Singh, K. et al. Correcting the drug development paradigm for glioblastoma requires serial tissue sampling. <italic>Nat. Med.</italic><bold>29</bold>, 2402&#x02013;2405 (2023).<pub-id pub-id-type="pmid">37488293</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Hotchkiss</surname><given-names>KM</given-names></name><etal/></person-group><article-title>A brave new framework for glioma drug development</article-title><source>Lancet Oncol.</source><year>2024</year><volume>25</volume><fpage>e512</fpage><lpage>e519</lpage><pub-id pub-id-type="pmid">39362262</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Hotchkiss, K. M. et al. A brave new framework for glioma drug development. <italic>Lancet Oncol.</italic><bold>25</bold>, e512&#x02013;e519 (2024).<pub-id pub-id-type="pmid">39362262</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Reardon</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial</article-title><source>JAMA Oncol.</source><year>2020</year><volume>6</volume><fpage>1003</fpage><lpage>1010</lpage><pub-id pub-id-type="pmid">32437507</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Reardon, D. A. et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. <italic>JAMA Oncol.</italic><bold>6</bold>, 1003&#x02013;1010 (2020).<pub-id pub-id-type="pmid">32437507</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Tawbi</surname><given-names>HA</given-names></name><etal/></person-group><article-title>Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study</article-title><source>Lancet Oncol.</source><year>2021</year><volume>22</volume><fpage>1692</fpage><lpage>1704</lpage><pub-id pub-id-type="pmid">34774225</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Tawbi, H. A. et al. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. <italic>Lancet Oncol.</italic><bold>22</bold>, 1692&#x02013;1704 (2021).<pub-id pub-id-type="pmid">34774225</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Johanns</surname><given-names>TM</given-names></name><etal/></person-group><article-title>Immunogenomics of hypermutated glioblastoma: a patient with germline <italic>POLE</italic> deficiency treated with checkpoint blockade immunotherapy</article-title><source>Cancer Discov.</source><year>2016</year><volume>6</volume><fpage>1230</fpage><lpage>1236</lpage><pub-id pub-id-type="pmid">27683556</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Johanns, T. M. et al. Immunogenomics of hypermutated glioblastoma: a patient with germline <italic>POLE</italic> deficiency treated with checkpoint blockade immunotherapy. <italic>Cancer Discov.</italic><bold>6</bold>, 1230&#x02013;1236 (2016).<pub-id pub-id-type="pmid">27683556</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Bouffet</surname><given-names>E</given-names></name><etal/></person-group><article-title>Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency</article-title><source>J. Clin. Oncol.</source><year>2016</year><volume>34</volume><fpage>2206</fpage><lpage>2211</lpage><pub-id pub-id-type="pmid">27001570</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Bouffet, E. et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. <italic>J. Clin. Oncol.</italic><bold>34</bold>, 2206&#x02013;2211 (2016).<pub-id pub-id-type="pmid">27001570</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>GV</given-names></name><etal/></person-group><article-title>Overall survival and response with nivolumab and relatlimab in advanced melanoma</article-title><source>NEJM Evid.</source><year>2023</year><volume>2</volume><fpage>EVIDoa2200239</fpage><pub-id pub-id-type="pmid">38320023</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Long, G. V. et al. Overall survival and response with nivolumab and relatlimab in advanced melanoma. <italic>NEJM Evid.</italic><bold>2</bold>, EVIDoa2200239 (2023).<pub-id pub-id-type="pmid">38320023</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Tawbi</surname><given-names>HA</given-names></name><etal/></person-group><article-title>Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma</article-title><source>N. Engl. J. Med.</source><year>2022</year><volume>386</volume><fpage>24</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">34986285</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Tawbi, H.A. et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. <italic>N. Engl. J. Med.</italic><bold>386</bold>, 24&#x02013;34 (2022).<pub-id pub-id-type="pmid">34986285</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Kesari</surname><given-names>S</given-names></name><etal/></person-group><article-title>Prospective phase I study of checkpoint blockade for the treatment of patients with newly diagnosed high-grade glioma prior to radiochemotherapy: results of nivolumab plus ipilimumab treatment arm</article-title><source>J. Clin. Oncol.</source><year>2023</year><volume>41</volume><fpage>2057</fpage></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Kesari, S. et al. Prospective phase I study of checkpoint blockade for the treatment of patients with newly diagnosed high-grade glioma prior to radiochemotherapy: results of nivolumab plus ipilimumab treatment arm. <italic>J. Clin. Oncol.</italic><bold>41</bold>, 2057 (2023).</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Raimbault</surname><given-names>A</given-names></name><etal/></person-group><article-title>Radionecrosis of malignant glioma and cerebral metastasis: a diagnostic challenge in MRI</article-title><source>Diagn. Interv. Imaging</source><year>2014</year><volume>95</volume><fpage>985</fpage><lpage>1000</lpage><pub-id pub-id-type="pmid">25001364</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Raimbault, A. et al. Radionecrosis of malignant glioma and cerebral metastasis: a diagnostic challenge in MRI. <italic>Diagn. Interv. Imaging</italic><bold>95</bold>, 985&#x02013;1000 (2014).<pub-id pub-id-type="pmid">25001364</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach</article-title><source>J. Transl. Med.</source><year>2023</year><volume>21</volume><fpage>257</fpage><pub-id pub-id-type="pmid">37055772</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Mao, Y. et al. Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach. <italic>J. Transl. Med.</italic><bold>21</bold>, 257 (2023).<pub-id pub-id-type="pmid">37055772</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Foroutan</surname><given-names>M</given-names></name><etal/></person-group><article-title>Single sample scoring of molecular phenotypes</article-title><source>BMC Bioinformatics</source><year>2018</year><volume>19</volume><fpage>404</fpage><pub-id pub-id-type="pmid">30400809</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Foroutan, M. et al. Single sample scoring of molecular phenotypes. <italic>BMC Bioinformatics</italic><bold>19</bold>, 404 (2018).<pub-id pub-id-type="pmid">30400809</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Mann</surname><given-names>GB</given-names></name><etal/></person-group><article-title>Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm study</article-title><source>Lancet</source><year>2024</year><volume>403</volume><fpage>261</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">38065194</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Mann, G. B. et al. Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm study. <italic>Lancet</italic><bold>403</bold>, 261&#x02013;270 (2024).<pub-id pub-id-type="pmid">38065194</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Agafonov</surname><given-names>O</given-names></name><name><surname>Azab</surname><given-names>A</given-names></name><name><surname>Stokowy</surname><given-names>T</given-names></name><name><surname>Hovig</surname><given-names>E</given-names></name></person-group><article-title>Accuracy and efficiency of germline variant calling pipelines for human genome data</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>20222</fpage><pub-id pub-id-type="pmid">33214604</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Zhao, S., Agafonov, O., Azab, A., Stokowy, T. &#x00026; Hovig, E. Accuracy and efficiency of germline variant calling pipelines for human genome data. <italic>Sci. Rep.</italic><bold>10</bold>, 20222 (2020).<pub-id pub-id-type="pmid">33214604</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="other">Behera, S. et al. Comprehensive genome analysis and variant detection at scale using DRAGEN. <italic>Nat. Biotechnol.</italic>10.1038/s41587-024-02382-1 (2024).</mixed-citation></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Priestley</surname><given-names>P</given-names></name><etal/></person-group><article-title>Pan-cancer whole-genome analyses of metastatic solid tumours</article-title><source>Nature</source><year>2019</year><volume>575</volume><fpage>210</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">31645765</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Priestley, P. et al. Pan-cancer whole-genome analyses of metastatic solid tumours. <italic>Nature</italic><bold>575</bold>, 210&#x02013;216 (2019).<pub-id pub-id-type="pmid">31645765</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Ahdesm&#x000e4;ki</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Prioritisation of structural variant calls in cancer genomes</article-title><source>PeerJ</source><year>2017</year><volume>5</volume><fpage>e3166</fpage><pub-id pub-id-type="pmid">28392986</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Ahdesm&#x000e4;ki, M. J. et al. Prioritisation of structural variant calls in cancer genomes. <italic>PeerJ</italic><bold>5</bold>, e3166 (2017).<pub-id pub-id-type="pmid">28392986</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Black</surname><given-names>S</given-names></name><etal/></person-group><article-title>CODEX multiplexed tissue imaging with DNA-conjugated antibodies</article-title><source>Nat. Protoc.</source><year>2021</year><volume>16</volume><fpage>3802</fpage><lpage>3835</lpage><pub-id pub-id-type="pmid">34215862</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Black, S. et al. CODEX multiplexed tissue imaging with DNA-conjugated antibodies. <italic>Nat. Protoc.</italic><bold>16</bold>, 3802&#x02013;3835 (2021).<pub-id pub-id-type="pmid">34215862</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Bankhead</surname><given-names>P</given-names></name><etal/></person-group><article-title>QuPath: open source software for digital pathology image analysis</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>16878</fpage><pub-id pub-id-type="pmid">29203879</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. <italic>Sci. Rep.</italic><bold>7</bold>, 16878 (2017).<pub-id pub-id-type="pmid">29203879</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Palla</surname><given-names>G</given-names></name><etal/></person-group><article-title>Squidpy: a scalable framework for spatial omics analysis</article-title><source>Nat. Methods</source><year>2022</year><volume>19</volume><fpage>171</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">35102346</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Palla, G. et al. Squidpy: a scalable framework for spatial omics analysis. <italic>Nat. Methods</italic><bold>19</bold>, 171&#x02013;178 (2022).<pub-id pub-id-type="pmid">35102346</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Shannon</surname><given-names>CE</given-names></name></person-group><article-title>A mathematical theory of communication</article-title><source>Bell Syst. Tech. J.</source><year>1948</year><volume>27</volume><fpage>379</fpage><lpage>423</lpage></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Shannon, C. E. A mathematical theory of communication. <italic>Bell Syst. Tech. J.</italic><bold>27</bold>, 379&#x02013;423 (1948).</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="other">Wickham, H., Fran&#x000e7;ois, R., Henry, L., M&#x000fc;ller, K. &#x00026; Vaughan, D. dplyr: a grammar of data manipulation. R package version 1.1.4 <ext-link ext-link-type="uri" xlink:href="https://dplyr.tidyverse.org">https://dplyr.tidyverse.org</ext-link> (2023).</mixed-citation></ref><ref id="CR48"><label>48.</label><mixed-citation publication-type="other">R Core Team. <italic>R: A Language and Environment for Statistical Computing</italic> (R Project for Statistical Computing, 2023).</mixed-citation></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Wickham</surname><given-names>H</given-names></name><etal/></person-group><article-title>Welcome to the Tidyverse</article-title><source>J. Open Source Software</source><year>2019</year><volume>4</volume><fpage>1686</fpage></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Wickham, H. et al. Welcome to the Tidyverse. <italic>J. Open Source Software</italic><bold>4</bold>, 1686 (2019).</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Yeo</surname><given-names>D</given-names></name><etal/></person-group><article-title>Accurate isolation and detection of circulating tumor cells using enrichment-free multiparametric high resolution imaging</article-title><source>Front. Oncol.</source><year>2023</year><volume>13</volume><fpage>1141228</fpage><pub-id pub-id-type="pmid">37051527</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Yeo, D. et al. Accurate isolation and detection of circulating tumor cells using enrichment-free multiparametric high resolution imaging. <italic>Front. Oncol.</italic><bold>13</bold>, 1141228 (2023).<pub-id pub-id-type="pmid">37051527</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>